Kristie L. Kahl is vice president of content at MJH Life Sciences, overseeing CURE®, CancerNetwork®, the journal ONCOLOGY, Targeted Oncology, and Urology Times®. She has been with the company since November 2017.
She is a graduate of Rider University, where she acquired a Bachelors of Art in journalism, as well as a graduate of Temple University, where she received her Masters of Science in Sports Management.
Follow Kristie on Twitter at @KristieLKahl, or email her at kkahl@mjhlifesciences.com.
FDA Grants Fast Track Designation to Selinexor to Treat Diffuse Large B-cell Lymphoma
November 7th 2018The Food and Drug Administration (FDA) granted fast track designation to selinexor for the treatment of patients with diffuse large B-cell lymphoma (DLBCL), according to Karyopharm Therapeutics, the drug’s manufacturer.
Read More
FDA Approves Lorbrena for Metastatic Non-Small Cell Lung Cancer Subtype
November 3rd 2018The Food and Drug Administration (FDA) granted accelerated approval to Lorbrena (lorlatinib) for the treatment of patients with ALK-positive, metastatic non-small cell lung cancer (NSCLC) who progressed on one or more ALK tyrosine kinase inhibitor (TKI), according to Pfizer, the drug’s manufacturer.
Read More
FDA Grants Priority Review to Jakafi for Acute Graft-Versus-Host-Disease
October 26th 2018The Food and Drug Administration has granted a priority review to the supplemental new drug application for Jakafi (ruxolitinib) to treat patients with acute graft-versus-host-disease (GVHD) who have had an inadequate response to corticosteroids.
Read More
Replacing Agent in R-CHOP Regimen Improves Survival in Mantle Cell Lymphoma
October 26th 2018The replacement of vincristine with Velcade (bortezomib) in the R-CHOP regimen for the treatment of transplantation-ineligible patients with newly diagnosed mantle cell lymphoma improved overall survival in a final analysis of the LYM-3002 trial.
Read More
Joining Forces Against Hereditary Risk for Breast and Ovarian Cancer
October 24th 2018After receiving a breast cancer diagnosis “out of the blue” in 1996, Sue Friedman would later come to find out she also has a BRCA2 genetic mutation – a discovery that would lead to the creation of an organization for individuals in a similar situation.
Read More
Patients with Advanced Lung Cancer Receive Unnecessary Medicine at Hospital Discharge
October 17th 2018The amount of preventative medicines given during hospital admission may be associated with an increased amount prescribed at discharge – resulting in higher costs and an increased risk for drug-drug interactions in patients with advanced lung cancer.
Read More
Talking Below the Belt with Real Housewife Camille Grammer
October 13th 2018In this week’s special edition of CURE Talks Cancer, we spoke with Bravo TV’s “Real Housewives of Beverly Hills” star Camille Grammer about her experience with uterine cancer, and the advocacy work she does for “below the belt” cancers.
Read More
Pregnant With Cancer: How One Woman's Life Changed In Just Three Days
October 11th 2018Eleven years ago, Stephanie Hosford received two pieces of life-changing news within the span of three days: she was diagnosed with triple-negative breast cancer and she found out she was pregnant – all while going through an adoption process at the same time.
Read More